Digitisation | November 14, 2023
Bayer and Recursion focus research collaboration on Oncology
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
The new gummy capabilities include a dedicated R&D lab, an automated production line, and bottle packaging solutions
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated
